曲妥珠单抗:准备和计划将避免混乱

Future Prescriber Pub Date : 2008-08-08 DOI:10.1002/fps.19

Steve Chaplin MRPharmS

{"title":"曲妥珠单抗:准备和计划将避免混乱","authors":"Steve Chaplin MRPharmS","doi":"10.1002/fps.19","DOIUrl":null,"url":null,"abstract":"<p>Trastuzumab has been shown to improve disease-free, and overall, survival in women with early HER2-positive breast cancer. It is undergoing rapid appraisal by NICE with the aim of providing prompt guidance for use within the NHS. The DOH has pledged to support its use, yet without increasing PCT funding for support services and additional drug costs. The criteria by which PCTs can decide or decline to pay for treatment remain unclear. Copyright © 2006 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"7 1","pages":"7-12"},"PeriodicalIF":0.0000,"publicationDate":"2008-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.19","citationCount":"0","resultStr":"{\"title\":\"Trastuzumab: preparation and planning will avoid chaos\",\"authors\":\"Steve Chaplin MRPharmS\",\"doi\":\"10.1002/fps.19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Trastuzumab has been shown to improve disease-free, and overall, survival in women with early HER2-positive breast cancer. It is undergoing rapid appraisal by NICE with the aim of providing prompt guidance for use within the NHS. The DOH has pledged to support its use, yet without increasing PCT funding for support services and additional drug costs. The criteria by which PCTs can decide or decline to pay for treatment remain unclear. Copyright © 2006 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"7 1\",\"pages\":\"7-12\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.19\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Trastuzumab: preparation and planning will avoid chaos

Trastuzumab has been shown to improve disease-free, and overall, survival in women with early HER2-positive breast cancer. It is undergoing rapid appraisal by NICE with the aim of providing prompt guidance for use within the NHS. The DOH has pledged to support its use, yet without increasing PCT funding for support services and additional drug costs. The criteria by which PCTs can decide or decline to pay for treatment remain unclear. Copyright © 2006 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量